Noom, Found, and Hims & Hers have all launched programs to prescribe \u201cmicrodosed\u201d GLP-1s in the last three months, following in the footsteps of many smaller direct-to-consumer telehealth companies. Microdosing is getting a shot of promotion from Hollywood, too: Noom has promoted its program alongside a new celebrity spokesperson, actor Rebel Wilson, and TV host Andy Cohen has been doing the rounds talking about his microdosing habit.\u00a0<\/p>\n
In their marketing, telehealth companies claim that compounded GLP-1s in small doses \u2014 starting lower than FDA-approved doses from Novo Nordisk and Eli Lilly \u2014 can reduce metabolic risk, lower inflammatory markers, and even lower the risk of cognitive decline.\u00a0<\/p>\n
Physicians and researchers say there is no robust clinical evidence that semaglutide or tirzepatide are effective at very small doses, and the drugs aren\u2019t proven to help patients with many marketed symptoms. \u201cEssentially these patients are guinea pigs, both on the efficacy side and the safety side,\u201d said Reshma Ramachandran, a health services researcher and clinician at the Yale School of Medicine.<\/p>\n
STAT+ Exclusive Story<\/p>\n
Already have an account? Log in<\/a><\/p>\n \t\t\t \t\t\t\t\t \t\t\t\tThis article is exclusive to STAT+ subscribers Already have an account? Log in<\/a><\/p>\n \t\t\t\t\t\tIndividual plans<\/p>\n \t\t\t\t\t\tGroup plans<\/p>\n![\"STAT+\"\/](\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2025\/09\/stat-plus-breaker-bg.png\")
<\/p>\n
\n\t\t\t\t\t\t![\"STAT+\"\/](\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\"){kind=logo}
\n\t\t\t\t\t<\/a><\/p>\n
\n\t\t\t\tUnlock this article \u2014 and get additional analysis of the technologies disrupting health care \u2014 by subscribing to STAT+.<\/p>\n